Retrograde mitochondrial signaling governs the identity and maturity of metabolic tissues.

Summary

Across β cells, hepatocytes, and brown adipocytes, loss of mitochondrial quality control activates a mitonuclear stress program that reduces cellular identity and maturity via the integrated stress response and chromatin remodeling. In vivo pharmacologic ISR inhibition restored β-cell identity, nominating retrograde mitochondrial signaling as a therapeutic entry point for metabolic disease.

Key Findings

• Deficiencies in mitochondrial genome integrity, dynamics, or turnover impair oxidative phosphorylation and activate the mitochondrial integrated stress response.
• Mitonuclear signaling triggers chromatin remodeling and cellular immaturity in β cells, hepatocytes, and brown adipocytes rather than apoptosis.
• In vivo pharmacologic blockade of the integrated stress response restores β-cell identity after loss of mitochondrial quality control.

Clinical Implications

Suggests ISR modulators could preserve or restore β-cell identity and function in diabetes and potentially improve hepatic and brown adipose metabolic programs. Encourages biomarker development for mitonuclear stress states in human metabolic disease.

Limitations

• Primarily preclinical; translational efficacy and safety of ISR blockade in humans remain untested.
• Extent to which similar mitonuclear de-differentiation occurs in human metabolic disease tissues requires confirmation.

Future Directions

Define biomarkers of mitonuclear stress in human diabetes, test ISR/mitonuclear pathway inhibitors clinically, and map chromatin remodeling targets underlying cellular immaturity.